Protalix BioTherapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2016 | 294.9% | 294.9% | -35.7% |
| FY2017 | 283.3% | 283.3% | -115.5% |
| FY2018 | 50.0% | 50.0% | -43.3% |
| FY2019 | 26.0% | 26.0% | -40.3% |
| FY2020 | 24.1% | 24.1% | -9.6% |
| FY2021 | 457.0% | 457.0% | -37.4% |
| FY2022 | 140.3% | 140.3% | -26.8% |
| FY2023 | 24.8% | 24.8% | 9.8% |
| FY2024 | 6.8% | 6.8% | 4.0% |
| FY2025 | -13.7% | -13.7% | -8.0% |